Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group
Advanced solid tumors represent a significant challenge in oncology, characterized
by their resistance to conventional therapies and their potential to metastasize,
leading to poor prognosis for patients. These tumors are often defined
by their stage, typically stage III or IV, indicating local invasion or
distant spread. Common types include advanced stages of breast, lung,
colorectal, and pancreatic cancers, among others.
Advanced solid tumors studies are a novel design in oncology clinical
trials that test the effect of a drug targeting a specific mutation or
molecular alteration across multiple cancer types. Unlike traditional
clinical trials that focus on a single cancer type, basket studies group
patients based on the presence of a particular biomarker, regardless of
where the cancer originated in the body.
Key features of these studies include:
- Biomarker-driven approach
- Multiple cancer types in one trial
- Usually single-arm design
- Potential for faster drug development
These studies are particularly useful for rare cancers and for evaluating
targeted therapies. They can provide valuable insights into the efficacy
of a treatment across various tumor types that share a common genetic
alteration.
Providence Medical Group is currently enrolling patients for the following
advanced solid tumor clinical trials:
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability,
Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination
with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing
Claudin 18.2 (CLARITY-PanTumour01)
Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as
Monotherapy and in Combination to Patients with Advanced or Metastatic
Solid Tumors
Treatment agent: ART0380 + Irinotecan
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
Study Details | A Study of ART0380 for the Treatment of Advanced or Metastatic
Solid Tumors | ClinicalTrials.gov
Sponsor: Artios Pharma Ltd.
Location: Providence Cancer Center, Santa Rosa, CA
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the
Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects
with Solid Tumors or Lymphoma
Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression
Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA
Bluestar study to test a new drug in participants with advanced or metastatic
ovarian, endometrial or HER2-breast cancer
Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC).
Physician:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic
Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A study of Dato-Dxd as monotherapy and in combination with anti-cancer
agents in patients with advanced solid tumors: AZ D926UC00001 Tropion
Pan-Tumor 03.
Treatment agent: Datopotamab Deruxtecan- an ADC comprised of a recombinant
humanized anti-TROP2 IgG1 mAb
Physician:
Yao Yao Pollock, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents
in Patients With Advanced Solid Tumours (TROPION-PanTumor03) - Full Text
View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA
Study for participants with selected HER2 expressing tumors: biliary tract,
bladder, endometrial, ovarian, pancreatic, and rare tumors (Destiny Pan-Tumor 2)
Treatment agent: trastuzumab deruxtecan (T-DXd)
Physician: Dr Ian Anderson
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Phase 2 Study of T-DXd in Patients With Selected HER2
Expressing Tumors | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug
Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono
MS202329-0010 PROCEADE)